These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37965317)

  • 1. The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.
    Lonie JM; Brosda S; Bonazzi VF; Aoude LG; Patel K; Brown I; Sharma S; Lampe G; Addala V; Koufariotis LT; Wood S; Waddell N; Dolcetti R; Barbour AP
    Front Immunol; 2023; 14():1220129. PubMed ID: 37965317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High CD8
    Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
    Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma.
    Belle CJ; Lonie JM; Brosda S; Barbour AP
    Front Immunol; 2023; 14():1330635. PubMed ID: 38155973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.
    Soeratram TT; Creemers A; Meijer SL; de Boer OJ; Vos W; Hooijer GK; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; Lei M; Bijlsma MF; Ylstra B; van Grieken NC; van Laarhoven HW
    J Pathol; 2022 Mar; 256(3):282-296. PubMed ID: 34743329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
    Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
    Kamarajah SK; Phillips AW; Ferri L; Hofstetter WL; Markar SR
    Br J Surg; 2021 Apr; 108(4):403-411. PubMed ID: 33755097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.
    Noble F; Mellows T; McCormick Matthews LH; Bateman AC; Harris S; Underwood TJ; Byrne JP; Bailey IS; Sharland DM; Kelly JJ; Primrose JN; Sahota SS; Bateman AR; Thomas GJ; Ottensmeier CH
    Cancer Immunol Immunother; 2016 Jun; 65(6):651-62. PubMed ID: 27020682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic and immunosuppressive inflammatory cells predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma.
    Göbel HH; Büttner-Herold MJ; Fuhrich N; Aigner T; Grabenbauer GG; Distel LVR
    Radiother Oncol; 2020 May; 146():151-160. PubMed ID: 32169773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells.
    He Y; Yang D; Lin X; Zhang J; Cheng R; Cao L; Yang L; Zhang M; Shi X; Jin X; Sun H; Sun H; Zang J; Li Y; Ma J; Nie H
    Front Immunol; 2024; 15():1412693. PubMed ID: 39076970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
    Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma.
    Goedegebuure RSA; Harrasser M; de Klerk LK; van Schooten TS; van Grieken NCT; Eken M; Grifhorst MS; Pocorni N; Jordanova ES; van Berge Henegouwen MI; Pouw RE; Verheul HMW; van der Vliet JJ; van Laarhoven HWM; Thijssen VLJL; Bass AJ; De Gruijl TD; Derks S
    Oncoimmunology; 2021; 10(1):1954807. PubMed ID: 34377591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer.
    Yamamoto K; Makino T; Sato E; Noma T; Urakawa S; Takeoka T; Yamashita K; Saito T; Tanaka K; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Mori M; Doki Y; Wada H
    Cancer Sci; 2020 Apr; 111(4):1103-1112. PubMed ID: 31981293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer.
    van Eijck CWF; Mustafa DAM; Vadgama D; de Miranda NFCC; Groot Koerkamp B; van Tienhoven G; van der Burg SH; Malats N; van Eijck CHJ;
    Gut; 2024 Jan; 73(2):311-324. PubMed ID: 37709493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.
    Turkington RC; Knight LA; Blayney JK; Secrier M; Douglas R; Parkes EE; Sutton EK; Stevenson L; McManus D; Halliday S; McCavigan AM; Logan GE; Walker SM; Steele CJ; Perner J; Bornschein J; MacRae S; Miremadi A; McCarron E; McQuaid S; Arthur K; James JA; Eatock MM; O'Neill R; Noble F; Underwood TJ; Harkin DP; Salto-Tellez M; Fitzgerald RC; Kennedy RD;
    Gut; 2019 Nov; 68(11):1918-1927. PubMed ID: 30852560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.
    Abdul Sater H; Marté JL; Donahue RN; Walter-Rodriguez B; Heery CR; Steinberg SM; Cordes LM; Chun G; Karzai F; Bilusic M; Harmon SA; Turkbey IB; Choyke PL; Schlom J; Dahut WL; Madan RA; Pinto PA; Gulley JL
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32269146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
    Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
    Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.
    Donlon NE; Davern M; O'Connell F; Sheppard A; Heeran A; Bhardwaj A; Butler C; Narayanasamy R; Donohoe C; Phelan JJ; Lynam-Lennon N; Dunne MR; Maher S; O'Sullivan J; Reynolds JV; Lysaght J
    World J Gastroenterol; 2022 Jun; 28(21):2302-2319. PubMed ID: 35800186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis.
    Xing X; Shi J; Jia Y; Dou Y; Li Z; Dong B; Guo T; Cheng X; Li X; Du H; Hu Y; Jia S; Zhang J; Li Z; Ji J
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35361730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.